SciBase Strengthens Its Position with a New Patent
SciBase Holding AB (STO: SCIB), a prominent player in the medical technology sector, is excited to announce the successful acquisition of a new European patent. This patent, numbered EP3876835B1 and titled "Medical Devices for Analyzing Epithelial Barrier Function," significantly enhances the company's intellectual property assets, which play a vital role in its growth strategy.
The patent empowers SciBase to advance its innovative technologies, which aim to provide a deeper understanding of the epithelial skin barrier, pivotal in diagnosing skin-related conditions. This patent moves the company closer to its goal of developing groundbreaking medical and research solutions.
Enhancing Patient Care with New Technologies
Pia Renaudin, the CEO of SciBase, expressed enthusiasm about the patent, emphasizing the company’s commitment to innovation. "The ability to protect our advancements through patents is crucial. This recent achievement solidifies our market position and underscores the immense potential we foresee in our field," she remarked. Renaudin extended her gratitude to Professor Cezmi Akdis for his significant contributions to the patent's development.
The patented technology focuses on the assessment and monitoring of epithelial barrier function in living subjects through electrical impedance measurements. This innovative approach has multiple applications:
Key Applications of the Patent:
- Detecting drug effects and evaluating patient responses related to the epithelial skin barrier.
- Introducing an enhanced medical device designed for screening epithelial skin barrier function.
- Employing a reliable analytical method insusceptible to environmental influences for studying epithelial skin barriers.
The patent is set to expire in 2039 and extends PCT protections across Europe, highlighting the global reach of SciBase's innovative capabilities.
A Vision for the Future of Dermatology
With a focus on improving skin health, SciBase strives to minimize patient suffering through early detection and intervention in dermatological conditions. The company's flagship product, Nevisense, represents a unique point-of-care platform that utilizes artificial intelligence and advanced electrical impedance spectroscopy (EIS) technology. This platform aims to enhance diagnostic accuracy and, ultimately, the quality of skin healthcare.
The commitment of SciBase to advancing dermatological care is built on over two decades of rigorous research conducted at the esteemed Karolinska Institute in Sweden. The company aims not only to improve patient outcomes but also to reduce healthcare costs, demonstrating a holistic approach to health technology.
Company Overview and Contact Information
SciBase has been listed on the Nasdaq First North Growth Market since June 2015, providing a solid foundation for its innovative journey in the medical technology industry. For inquiries or further details about the company and its products, please feel free to reach out to the following:
Pia Renaudin, CEO
Phone: +46732069802
Email: [contact information]
Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
Email: [contact information]
Frequently Asked Questions
What is the significance of the new patent?
The new patent reinforces SciBase's commitment to innovation in dermatology by allowing them to safeguard their developments in analyzing skin barrier function.
How does the patented technology work?
The technology assesses the epithelial barrier function through electrical impedance measurements in living subjects, providing insights into skin health.
What is Nevisense?
Nevisense is SciBase's unique point-of-care platform that combines AI and EIS technology to improve diagnostic accuracy in dermatology.
Who contributed to the patent development?
Professor Cezmi Akdis played a significant role in the formulation and data collection phases of the patent application.
What is SciBase's mission?
SciBase aims to enhance patient care by minimizing suffering through early detection, timely intervention, and improving diagnostics in dermatology.
